View Older Stories View More Recent Stories
-
Hims & Hers Health (HIMS) Mentioned as Long by Short Seller Hunterbrook
-
BofA Securities on Hims and Hers (HIMS): 'Trump’s FDA nominee currently works for a GLP-1 compounder'
-
Hims & Hers Health, Inc. (HIMS) Trades at High, Up 12%
-
Hims & Hers Health (HIMS) Expands Nutrition Support to Fuel Customers’ Weight Loss Journeys
-
Hims & Hers Health, Inc. (HIMS) call put ratio 1 call to 1.5 puts on active option volume of 101K contracts
-
Archegos Founder Bill Hwang Sentenced To 18 Years In Prison
-
TD Cowen Reiterates Buy Rating on Hims and Hers (HIMS)
-
Hims & Hers Health, Inc. (HIMS) call put ratio 1.1 calls to 1 put amid wide price movement
-
Hims & Hers Health, Inc. (HIMS) call put ratio 1.1 calls to 1 put as share price down 5.2%
-
Hims & Hers Health, Inc. (HIMS) options active on volume of 274K contracts
-
Hims & Hers Health, Inc. (HIMS) options active on 274K contracts amid wide price movement
-
BofA Securities Downgrades Hims and Hers (HIMS) to Underperform
-
Increasing unusual put option volume: ZETA IGV TGTX QXO HIMS INDA MT LUNR PAGS RKLB RITM
-
Hims & Hers Health, Inc. (HIMS) Weakness Tied to Amazon Telehealth Offering
-
Hims and Hers (HIMS) PT Raised to $21 at Piper Sandler
-
Hims and Hers (HIMS) PT Raised to $28 at Needham
-
TD Cowen Reiterates Buy Rating on Hims and Hers (HIMS)
-
Hims and Hers (HIMS) PT Raised to $24 at Citi
-
Truist Securities Reiterates Hold Rating on Hims and Hers (HIMS)
-
Hims and Hers (HIMS) PT Raised to $27 at BofA Securities
-
After-hours movers: Palantir, Cleveland-Cliffs, Coinbase and more
-
Hims & Hers Health, Inc. (HIMS) Tops Q3 EPS by 22c; beats on guidance
-
Hims & Hers Health, Inc. (HIMS) Falls 14%
-
Hims and Hers (HIMS) PT Raised to $26 at Leerink Partners
-
Hims & Hers Health, Inc. (HIMS) Appoints Jessica Shepherd as Chief Medical Officer
-
Hims and Hers (HIMS) PT Raised to $25 at BofA Securities
-
Hims and Hers (HIMS) PT Raised to $23 at BofA Securities
-
Truist Securities Reiterates Hold Rating on Hims and Hers (HIMS)
-
Hims & Hers (HIMS) Climbs as FDA to Reconsider Decision Barring Compounded Versions of Eli Lilly (LLY) Weight Loss Drug
-
Canaccord Genuity Reiterates Buy Rating on Hims and Hers (HIMS)
-
Truist Securities Reiterates Hold Rating on Hims and Hers (HIMS)
-
Hims & Hers Health, Inc. (HIMS) to Join S&P SmallCap 600
-
Citi Reiterates Neutral Rating on Hims and Hers (HIMS)
-
Hims & Hers Health (HIMS) Falls 8% as Shortage of Lilly's (LLY) Weight-Loss Drug Ends
-
Hims & Hers Health, Inc. (HIMS) to Offer Access to Compounded GLP-1 Injections for as Low as $99/Month to U.S. Military, Veterans, Teachers, Nurses and First Responders
-
Hims & Hers Health (HIMS) Files Mixed Shelf
-
Truist Defending Viking Therapeutics (VKTX): 'recommend investors take advantage of today’s selloff to add to shares'
-
Hims & Hers Health, Inc. (HIMS) call put ratio 2.6 calls to 1 put after Eli Lilly & Co. (LLY) launches single-dose vials of Zepbound
-
Citi on Hims and Hers (HIMS) Post Lilly (LLY) News: 'Single-dose Zepbound Vials a Shot Across the Bow for the Compounders'
-
Hims & Hers Health, Inc. (HIMS) Declines 7%
-
Needham Starts Hims and Hers (HIMS) at Buy
-
Hims and Hers (HIMS) PT Lowered to $18 at Jefferies
-
Hims and Hers (HIMS) PT Raised to $23 at Deutsche Bank
-
After-hours movers: Palantir, ZoomInfo, Hims & Hers and more
-
Hims & Hers Health, Inc. (HIMS) Tops Q2 EPS by 2c, Offers Guidance
-
These stocks are near-term opportunity to invest in the GLP-1 space
-
Hims & Hers Health, Inc. (HIMS) Says 'Voluntarily Cooperating' With FTC Inquiry - Bloomberg
-
Hims and Hers (HIMS) PT Raised to $23 at Truist Securities
-
Hims and Hers (HIMS) PT Raised to $18 at Piper Sandler
-
Hims and Hers (HIMS) PT Raised to $25 at TD Cowen
